Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-06-06T15:33:03.763Z Has data issue: false hasContentIssue false
  • English
  • Français

Letter to the Editor: Critique of Bahorik et al. (2013) – 'Underreporting of drug use among individuals with schizophrenia: prevalence and predictors’ – a reply

Published online by Cambridge University Press:  28 October 2013

AMBER L. BAHORIK ,
CHRISTINA E. NEWHILL ,
COURTNEY C. QUEEN  and
SHAUN M. EACK
AMBER L. BAHORIK*
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA Western Psychiatric Institute and Clinic, University of Pittsburgh, PA, USA
CHRISTINA E. NEWHILL
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA
COURTNEY C. QUEEN
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA
SHAUN M. EACK
Affiliation:
School of Social Work, University of Pittsburgh, PA, USA Western Psychiatric Institute and Clinic, University of Pittsburgh, PA, USA
*
Author for correspondence: A. L. Bahorik, M.S.W. 3811 O'Hara Street, Webster Hall Suite 150, Pittsburgh, PA 15213, USA (Email: alb186@pitt.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
Psychological Medicine , Volume 44 , Issue 3 , February 2014 , pp. 670 - 671
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bahorik, AL, Newhill, CE, Queen, CC, Eack, SM (2013). Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychological Medicine. Published online 3 04 2013 . doi:10.1017/S0033291713000548.Google ScholarPubMed
Carey, K (2002). Clinically useful assessments: substance use and comorbid psychiatric disorders. Behaviour Research and Therapy 40, 1345–1361.Google Scholar
Donovan, D, Bigelow, G, Brigham, G, Carroll, K, Cohen, A, Gardin, J, Hamilton, J, Huestis, M, Lindbald, R, Marlatt, G, Preston, K, Selzer, J, Somoza, E, Wakim, P, Wells, E (2012). Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction 107, 694–708.CrossRefGoogle ScholarPubMed
McHugo, G, Drake, R, Brunette, M, Essock, S, Green, A (2006). Enhancing validity in co-occurring disorders treatment research. Schizophrenia Bulletin 32, 655–665.CrossRefGoogle ScholarPubMed
Van Dorn, R, Desmarais, SL, Swartz, MS, Young, MS, Sellers, BG (2013). Critique of Bahorik et al. (2013) – 'Underreporting of drug use among individuals with schizophrenia: prevalence and predictors’. Psychological Medicine. doi:10.1017/S0033291713002511.Google Scholar
Ziedonis, D, Smelson, D, Rosenthal, R, Batki, S, Green, A, Henry, R, Montoya, I, Parks, J, Weiss, R (2005). Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. Journal of Psychiatric Practice 11, 315–339.Google Scholar